A rewarding quarter for Diamyd Medical
In her Message from the CEO, contained in the Year End Report published today,
Elisabeth Lindner, President and CEO of Diamyd Medical, announced that the most
recent quarter has been a successful and intensive one for the Company.
During the last quarter of the fiscal year, Diamyd Medical has made considerable
progress with its successful start of the Phase III studies of the Diamyd®
diabetes vaccine. The Company also gained a great deal of exposure through
various conferences, publications and meetings. Above all the publication in the
world's most prestigious medical journal New England Journal of Medicine of the
results from a previous Diamyd® study with children suffering from type 1
diabetes has proven to be an enormous success.
“In today's turbulent financial climate, I am even more convinced that the
business model used by Diamyd, a flexible virtual company with low fixed costs,
is a determinative factor for stable growth and the achievement of our objective
of becoming a pharmaceutical company in the area of diabetes”, comments
Elisabeth Lindner, President and CEO of Diamyd.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
elisabeth.lindner@diamyd.com
Phone: +46-8-661 0026
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.),
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. VATno: SE556530-142001.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials are ongoing in both the US and Europe.
Furthermore, the company has initiated clinical studies within chronic pain,
using its Nerve Targeting Drug Delivery System (NTDDS). The company has also
out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
